NCT04617509View on ClinicalTrials.gov

A Study in Healthy Subjects to Evaluate Pharmacokinetics and Food Effect After Dosing of GS-248

PHASE1CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

March 31, 2020

Primary Completion Date

May 27, 2020

Study Completion Date

May 27, 2020

Conditions
Pharmacokinetic
Interventions
DRUG

Formulation A GS-248

Formulation A of GS-248 in a capsule, dose 120 mg given as a single-dose of 3 capsules a´40 mg.

DRUG

Formulation B GS-248

Formulation B of GS-248 in a capsule, dose 120 mg given as a single-dose of 3 capsules a´40 mg.

Trial Locations (1)

75237

Clinical Trial Consultants AB, Uppsala

Sponsors

Lead Sponsor

Gesynta Pharma AB
All Listed Sponsors
collaborator

CTC Clinical Trial Consultants AB

INDUSTRY

collaborator

Research Institutes of Sweden

OTHER

lead

Gesynta Pharma AB

INDUSTRY